Nektar Therapeutics | NKTR - 税前利润



金融业
股票价格
USD
资产
USD 280.41M
现金及等价物
USD 15.12M
销售成本
USD 4.44M
流动资产
USD 266.27M
流动负债
USD 53.54M
债务
USD 0
股息收益率
0
EBIT
USD -19.09M
EBITDA
USD -31.81M
员工
137
EPS每股收益
USD -1.35
股本和储备
USD 89.83M
销售毛利
USD 21.81M
债务利息支出
USD 9.77M
利息收入
USD -0.18
贷款资金
USD 63.16M
市值
USD 15.95B
净收入
USD -36.08M
营业费用
USD 40.9M
营业利润
USD -19.09M
普通股股本
USD 20.38M
税前利润
USD -34.7M
销售收入
USD 21.81M
销售和管理费用
USD 10.17M
股票
USD 14.46M
贸易债权人
USD 10.77M
应收帐款人
USD 1.78M


税前利润 更改 日
Agios Pharmaceuticals USD -99.11M 9.94M 2026-03
ALKERMES USD 60.38M 40.36M 2025-12
Alterity Therapeutics Limited AUD -4.74M 3.53M 2024-12
Amgen USD 1.51B 2.41B 2025-12
Baxter International USD -756M 877M 2025-12
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Biogen USD 377.7M 433.7M 2026-03
Bristol-Myers Squibb USD 1.47B 1.64B 2025-12
Cara Therapeutics USD -4.91M 3.17M 2025-03
Cipla INR 11.69B 6.85B 2025-12
Dr.Reddys Laboratories INR 15.68B 2.38B 2025-12
Eisai JPY 22B 7.47B 2025-12
Eli Lilly USD 8.27B 1.03B 2025-12
Esperion Therapeutics USD 63.67M 95M 2025-12
Exelixis USD 252.69M 275K 2025-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Grifols EUR 257.85M 190.87M 2024-12
Halozyme Therapeutics USD 218.96M 14.02M 2025-09
Incyte USD 343.6M 46.34M 2026-03
Ionis Pharmaceuticals USD -93M 135M 2026-03
Ironwood Pharmaceuticals USD 68.02M 30.2M 2025-09
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
MacroGenics USD -14.93M 31.75M 2025-12
Merck USD 3.42B 3.32B 2025-12
Nektar Therapeutics USD -34.7M 2.35M 2025-12
Neurocrine Biosciences USD 239.4M 52.4M 2025-12
Novartis USD 3.84B 802M 2026-03
Pfizer USD -1.64B 4.98B 2025-12
Roche Holding CHF 4.79B 3.01B 2025-06
Sarepta Therapeutics USD -407.67M 213.63M 2025-12
Takeda JPY 133.86B 105.69B 2025-12
Teva Pharmaceutical Industries USD 753M 662M 2026-03
Xencor USD -4.27M 1.76M 2025-12